Editas Medicine Stock News

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company. The biotech was mum on the reasoning for the termination, disclosed in

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc. (NASDAQ: AXSM ) disclosed in a filing that it reached a settlement with Baudax Bio, Inc. (NASDAQ: BXRX ) with regard to a lawsuit alleging that Axsome''s AXS-07 infringed a couple of patents owned by Baudax. Under the settlement agreement, Baudax is to voluntarily dismiss the lawsuit and Axsome will make a one-time payment of $312,500 to Baudax. Axsome has not incurred any obligation to pay any royalty or other contingent consideration nor has it agreed to any other restriction on its manufacture or distribution of AXS-07. Axsome shares were down 3.01% to $29.60 in premarket trading. Editas Announces Termination Of Chief Medical Office With Immediate Effect Editas Medicine, Inc. (NASDAQ: EDIT ) said in a filing with the SEC that Lisa Michaels'' employment with Editas as its chief medical officer was terminated, effective immediately.

Editas Medicine Inc EDIT has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Shares of Editas Medicine are down 7% in after-hours trading after the company said in a regulatory filing that Chief Medical Officer Lisa Michaels employment was terminated.

Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.

The following slide deck was published by Editas Medicine, Inc.

For these two companies, the rewards could end up outweighing the risks.

For these two companies, the rewards could end up outweighing the risks.

They've taken a beating, but the industries they track are still growing.

The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

The overall sell-off of biotech stocks appears to be the main culprit.